Needham Reiterates Buy on Collegium Pharmaceutical, Maintains $35 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Collegium Pharmaceutical (NASDAQ:COLL) and maintained a price target of $35.
August 04, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Collegium Pharmaceutical and maintained a price target of $35.
The reiteration of a 'Buy' rating by a Needham analyst indicates a positive outlook for Collegium Pharmaceutical. The maintained price target of $35 suggests that the analyst believes the stock is undervalued at current prices, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100